Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis
…, R Hunt, TD McHugh, CD Tweed… - … England Journal of …, 2022 - Mass Medical Soc
Background The bedaquiline–pretomanid–linezolid regimen has been reported to have 90%
efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with …
efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with …
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary …
CD Tweed, R Dawson, DA Burger… - The Lancet …, 2019 - thelancet.com
Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than
those that are currently available are needed as part of the global effort to address the …
those that are currently available are needed as part of the global effort to address the …
Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings …
…, K Sturgeon, K Scott, WJ Cragg, CD Tweed… - Trials, 2016 - Springer
Background Patient and public involvement (PPI) in studies carried out by the UK Medical
Research Council Clinical Trials Unit (MRC CTU) at University College London varies by …
Research Council Clinical Trials Unit (MRC CTU) at University College London varies by …
Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions
When designing a clinical trial, explicitly defining the treatment estimands of interest (that
which is to be estimated) can help to clarify trial objectives and ensure the questions being …
which is to be estimated) can help to clarify trial objectives and ensure the questions being …
Rethinking intercurrent events in defining estimands for tuberculosis trials
TM Pham, CD Tweed, JR Carpenter… - Clinical …, 2022 - journals.sagepub.com
Background/aims Tuberculosis remains one of the leading causes of death from an infectious
disease globally. Both choices of outcome definitions and approaches to handling events …
disease globally. Both choices of outcome definitions and approaches to handling events …
Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia
A South, P Dhesi, CD Tweed, B Tsogt… - Global Public …, 2023 - Taylor & Francis
We conducted qualitative research exploring the treatment experience of people with DR-TB.
We held nine focus group discussions with 57 adults undergoing/recently completed …
We held nine focus group discussions with 57 adults undergoing/recently completed …
Improving clinical trial interpretation with ACCEPT analyses
…, DT Dunn, M Quartagno, RM Turner, CD Tweed… - NEJM …, 2022 - evidence.nejm.org
… Clements, White, Copas, Dunn, Quartagno, Turner, Tweed, and Walker are supported by
core support from the Medical Research Council (MRC) UK to the MRC Clinical Trials Unit …
core support from the Medical Research Council (MRC) UK to the MRC Clinical Trials Unit …
Lung injury from e-cigarette use: a foul and pestilent congregation of vapours
R Chapman, CD Tweed, I Moonsie - BMJ Case Reports CP, 2020 - casereports.bmj.com
A 62-year-old man presented with worsening dyspnoea, haemoptysis and reduced exercise
tolerance. He was found to be hypoxaemic with bilateral basal opacification on chest …
tolerance. He was found to be hypoxaemic with bilateral basal opacification on chest …
Disseminating the research findings from the adolescents and adults living with Perinatal HIV (AALPHI) study: an approach from young people living with HIV
…, DM Gibb, M Le Prevost, W Mhizha, CD Tweed - Research Involvement …, 2024 - Springer
Background The Adolescents and Adults Living with Perinatal HIV (AALPHI) study is one of
only three cohort studies worldwide evaluating the impact of HIV on young people living with …
only three cohort studies worldwide evaluating the impact of HIV on young people living with …
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status
CD Tweed, AM Crook, R Dawson, AH Diacon… - BMC pulmonary …, 2019 - Springer
Background The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+
count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated …
count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated …
